Unicycive Therapeutics, Inc. (UNCY) - Dilution Analysis

10-K filing | 25.2M shares outstanding

10-Q filing | 17.7M shares outstanding

8-K filing: Stock split 1-for-10 | Outstanding: 120,629,281 → 12,768,239

10-Q filing | 120.6M shares outstanding

10-K filing | 119.7M shares outstanding

S-3 filing: Unicycive Therapeutics, Inc. files an S-3 registration statement to offer common stock, preferred stock, debt securities, and warrants up to an aggregate initial offering price not exceeding $100 million, and common stock up to $50 million via an at-the-market offering through Guggenheim Securities, LLC.

10-Q filing | 103.8M shares outstanding

10-Q filing | 94.4M shares outstanding

S-3 filing: Registration statement on Form S-3 providing for the resale by the Investors of the Common Stock issuable upon conversion of the Series B-1 Preferred Stock and Series B-2 Preferred Stock.

10-Q filing | 37.6M shares outstanding

10-K filing | 34.8M shares outstanding

8-K filing: Unicycive Therapeutics, Inc. entered into a securities purchase agreement to issue and sell 50,000 shares of Series B Convertible Preferred Stock at $1,000 per share in a private placement for $50 million, with an initial conversion price of $1.00 per share, subject to stockholder approval for conversion exceeding 19.99% of outstanding common stock. ($50.0M proceeds)

10-Q filing | 34.8M shares outstanding

10-Q filing | 34.8M shares outstanding

S-3 filing: The selling stockholders may offer and resell up to 111,017,635 shares of common stock pursuant to a Securities Purchase Agreement.

10-Q filing | 15.0M shares outstanding

10-K filing | 15.2M shares outstanding

8-K filing: The company filed a Certificate of Designation designating 30,190 shares as Series A-1 Preferred Stock, 1,800,000 shares as Series A-2 Preferred Stock, 1,800,000 shares as Series A-3 Convertible Preferred Stock, 1,800,000 shares as Series A-4 Convertible Preferred Stock, and 3,600,000 shares as Series A-5 Convertible Preferred Stock.

10-Q filing | 14.2M shares outstanding

S-3 filing: This S-3 filing indicates Unicycive Therapeutics, Inc. may offer and sell up to $50 million in various securities and also up to $3 million of common stock through an at-the-market offering.

10-Q filing | 15.1M shares outstanding

10-Q filing | 15.0M shares outstanding

10-K filing | 15.0M shares outstanding

10-Q filing | 15.0M shares outstanding

10-Q filing | 14.5M shares outstanding

S-1/A filing: This S-1/A filing relates to a proposed offering of units consisting of common stock and warrants, as well as an underwriter's option to purchase additional shares and/or warrants and a unit purchase option.

S-1/A filing: This S-1/A filing details an offering of units, each consisting of one share of common stock and four-fifth of a warrant, along with an underwriter option to purchase additional shares and warrants. The company intends to use the net proceeds for pre-clinical studies, clinical development, and general corporate purposes.

S-1/A filing: S-1/A filing for an offering of common stock and warrants with the intention to use the net proceeds from this offering to complete pre-clinical studies, including toxicology studies as recommended by the FDA, in connection with a New Drug Application (NDA) filing for Renazorb with the FDA.

S-1/A filing: This S-1/A filing outlines the offering of common stock and warrants, with an over-allotment option for additional shares and warrants. The net proceeds are intended for pre-clinical studies, clinical development, and general corporate purposes.

S-1/A filing: This S-1/A filing relates to a public offering of Unicycive Therapeutics, Inc.'s common stock, with Roth Capital Partners, LLC as the underwriter. The company intends to use the net proceeds from this offering to complete pre-clinical studies, including toxicology studies as recommended by the FDA, in connection with a New Drug Application (NDA) filing for Renazorb with the FDA. In addition, we plan to use proceeds to advance UNI 494 for pre-clinical development and the completion of Phase 1 and Phase 2 clinical studies for a potential IND filing in 2022.